Expertise in
13
conditions

Dr. Cheryl Hull

Dermatology
Hull Dermatology PA
500 S 52nd St, 
Rogers, AR 
Expertise in
13
conditions
Hull Dermatology PA
500 S 52nd St, 
Rogers, AR 

Overview

Cheryl Hull is a Dermatologist in Rogers, Arkansas. Dr. Hull is highly rated in 13 conditions, according to our data. Her top areas of expertise are Actinic Keratosis, Warts, Liver Spots, and Universal Acquired Melanosis.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Dermatology

Licenses

Dermatology in AR

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMO Partners
  • POS
HMSA
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Hull Dermatology PA
500 S 52nd St, Rogers, AR 72758
Other Locations
Office
599 S Horsebarn Rd, Rogers,, AR 72758

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug
Study Drug: LY3041658
Study Phase: Phase 2
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
Enrollment Status: Completed
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drug: AUR101
Study Phase: Phase 2
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
Enrollment Status: Completed
Publish Date: April 27, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 10 Less Clinical Trials

2 Total Publications

Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Journal: Pediatric dermatology
Published: December 05, 2019
Similar Doctors
Expertise in
77
conditions
Dr. Eric Stewart
Dermatology
Expertise in
77
conditions
Dr. Eric Stewart
Dermatology

Ozark Dermatology Clinic

4375 N Vantage Dr Ste 305, 
Fayetteville, AR 
 (16.7 miles away)
479-443-5100
Languages Spoken:
English
See accepted insurances

Eric Stewart is a Dermatologist in Fayetteville, Arkansas. Dr. Stewart is highly rated in 77 conditions, according to our data. His top areas of expertise are Giant Congenital Melanocytic Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Nevus, and Melanoma.

Expertise in
59
conditions
Dr. Robert Brown
Dermatology
Expertise in
59
conditions
Dr. Robert Brown
Dermatology

Office

901 SE 22nd St Ste 3, 
Bentonville, AR 
 (4.0 miles away)
479-273-7006
Languages Spoken:
English
See accepted insurances

Robert Brown is a Dermatologist in Bentonville, Arkansas. Dr. Brown is highly rated in 59 conditions, according to our data. His top areas of expertise are Actinic Keratosis, Seborrheic Keratosis, Warts, and Eosinophilic Pustular Folliculitis.

Expertise in
24
conditions
Dr. Christopher Schach
Dermatology
Expertise in
24
conditions
Dr. Christopher Schach
Dermatology

Ozark Dermatology Clinic

4375 N Vantage Dr Ste 305, 
Fayetteville, AR 
 (16.7 miles away)
479-443-5100
Languages Spoken:
English
See accepted insurances

Christopher Schach is a Dermatologist in Fayetteville, Arkansas. Dr. Schach is highly rated in 24 conditions, according to our data. His top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Actinic Keratosis, and Warts.

Frequently Asked Questions about Dr. Cheryl Hull

How do I make an appointment with Dr. Cheryl Hull?

You can book an appointment with Dr. Cheryl Hull by calling their office at 479-254-9662. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Cheryl Hull a top-rated expert for Actinic Keratosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cheryl Hull is classified as an Distinguished expert for Actinic Keratosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Cheryl Hull specialize in?

While Dr. Cheryl Hull is a Dermatology, they have specific expertise in Actinic Keratosis, Warts, and Liver Spots. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Cheryl Hull participate in research or clinical trials?

Yes. Dr. Cheryl Hull has published 2 articles and abstracts on conditions like Actinic Keratosis. You can view a list of Dr. Cheryl Hull's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Cheryl Hull accept my insurance?

Dr. Cheryl Hull accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 479-254-9662 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hull's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile